Clinic Roundup

Human Genome Sciences Inc., of Rockville, Md., and GlaxoSmithKline plc, of London, said data from the pivotal BLISS-52 study of Benlysta (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus was published in The Lancet. Data from that study, the first of two positive pivotal trials, originally were reported in 2009.